PM launches brain cancer review after meeting 'inspirational' patient

After meeting Archie Goodburn, Prime Minister Andy Burnham announced several measures to improve brain cancer care. They include appointing a national clinical lead, reviewing progress since 2018 and finding ways to get patients treatment sooner. The government said these steps matter because progress has been too slow for families facing the disease.

Professor Anthony Chalmers will lead the review. It will examine what has held progress back and will inform a national cancer plan. The plan aims to move new treatments from laboratories to patients faster. Burnham also asked the MHRA to complete its review of medicines for rare conditions within two years, rather than three.

Patients, families and charities will help design a programme to put more people into clinical trials. Health Secretary Yvette Cooper will lead that work. The measures apply across the United Kingdom through NIHR collaboration with devolved administrations.

Archie Goodburn is an Edinburgh-born Scottish swimmer who reached the 50m breaststroke final at the 2026 Commonwealth Games in Glasgow. He was diagnosed with three large, inoperable oligodendrogliomas after numbness and seizures during training for the 2024 Olympic trials. His treatment included chemotherapy and radiotherapy, but surgery was impossible.

Goodburn then spoke publicly about the gaps facing brain cancer patients. On BBC Breakfast, he said trials happening around the world were not being seen in the UK. He called that unfair and unjust, and made a tearful appeal for more investment in research. His experience gave a human face to delayed access and limited options.

After meeting Burnham, Goodburn said all three of his requests had been promised to some extent. The campaign helped secure a clinical lead, a progress review and work on quicker trials and treatments. His efforts also drew national attention to the disease's poor research record.

An oligodendroglioma is a rare type of cancer that can affect the brain and spinal cord. The article identifies Goodburn’s tumours as three large oligodendrogliomas. In general medical terms, these tumours develop from cells related to oligodendrocytes, which support nerve cells. The article itself does not describe their cellular origin.

Surgery may be impossible when a tumour is too close to vital brain structures, lies in a difficult location or cannot be removed safely. Removing it could cause major harm, so doctors may use other treatments. Goodburn received chemotherapy and radiotherapy because surgery to remove his tumours was found to be impossible.

The exact reason his tumours could not be operated on is not given in the article. It does show the serious treatment challenge: the tumours were large, and his care depended on non-surgical options. That makes faster research and access to trials especially important for patients with limited choices.

Professor Anthony Chalmers will lead a review of progress in brain cancer care and research since 2018. Its purpose is to identify what is still holding progress back. That matters because Prime Minister Andy Burnham said progress had not been good enough, while families cannot afford to wait for better options.

The review is expected to examine the sector’s development over the period beginning in 2018. Its findings will be followed by a national cancer plan. The stated goal is to move new treatments out of laboratories and into patient care faster. Patients, families and charities will also help shape a drive to increase clinical-trial participation.

The article does not explain why 2018 was selected as the starting point. It only states that progress will be assessed from that year. The review could therefore create a defined baseline for judging what has changed, what has failed to improve and what action is needed next.

A national clinical lead could give brain cancer care clearer leadership across the UK. This may help specialists, researchers and health services work toward shared priorities. The review led by Professor Anthony Chalmers is intended to expose barriers, while a national cancer plan would set out action to address them.

Faster medicines regulation could reduce the time needed to assess rules for treatments aimed at rare conditions. The prime minister asked the MHRA to complete its review in two years rather than three. More clinical trials could give eligible patients opportunities to receive treatments being tested, while generating evidence about whether those treatments work and are safe.

These measures do not guarantee that every patient will receive a new treatment. The government says patients, families and charities will help design a drive to put more people onto trials. The wider aim is to move discoveries from laboratories to patients faster and bring forward helpful regulatory changes.

Brain Tumour Research said charities provide more than 75% of total national investment in brain tumour research. Government funding accounts for 25%. These figures matter because research investment supports the discoveries, trials and treatment development that patients need, yet the disease remains a major cause of cancer deaths among younger people.

The funding split means charities are carrying most of the national research effort described in the article. Their support can help laboratories investigate disease and develop new options. Government funding is a smaller share, despite the need to move treatments from research into care. Goodburn’s campaign called for more investment and faster progress.

The announcement promises a renewed national focus, including a review and a plan to speed new treatments. Charity chief executive Dan Knowles welcomed that direction. However, the figures also reveal a continuing imbalance: the article does not announce a new funding percentage or a specific increase in government investment.

A clinical trial is a planned study involving people to test a potential treatment. It examines whether the treatment is safe, how well it works and how it compares with existing care. People usually join only when they meet the study’s requirements. The government wants more brain cancer patients to have access to suitable trials.

The pathway begins with laboratory research, where scientists investigate a possible treatment. If results support further development, researchers conduct safety checks and design studies in people. Regulators then assess medicines and the rules governing their use. The article says the MHRA is reviewing rules for medicines treating rare conditions and has been asked to complete that work sooner.

The government’s planned national cancer approach aims to move treatments out of the laboratory and to patients faster. Patients, families and charities will help design a drive to increase trial participation. The article does not provide detailed trial phases or approval requirements, so those steps are general medical context.